Immunohistochemical expression of apoptotic markers in drug-induced erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis

International Journal of Immunopathology and Pharmacology

Volumn 20, Issue 3, 2007, Pages 557-566

  Marzano, Angelo V ^a   Frezzolini, A ^b   Caproni, M ^c   Parodi, A ^d   Fanoni, D ^a   Quaglino, P ^e   Girgenti, V ^a   La Placa, M ^f   Fabbri, P ^c   Caputo, R ^a   Berti, E ^g  

^a UNIVERSITY OF MILAN   (Italy)

^b LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

^e UNIVERSITY OF TURIN   (Italy)

^f UNIVERSITY OF BOLOGNA   (Italy)

^g UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

Apoptosis; Erythema multiforme; Stevens Johnson syndrome; Toxic epidermal necrolysis

Indexed keywords

BIOLOGICAL MARKER; FAS ANTIGEN; FAS LIGAND; PROTEIN BAX; PROTEIN BCL 2;

APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG INDUCED DISEASE; ERYTHEMA MULTIFORME; HUMAN; IMMUNOHISTOCHEMISTRY; KERATINOCYTE; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS;

EID: 34948813529     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463200702000313     Document Type: Article

References (31)

1. Bastuji-Garin S., B. Rzany, R.S. Stern, N.H. Shear, L. Naldi and J.C. Roujeau. 1993. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch. Dermatol. 129:92.
2. Assier H., S. Bastuji-Garin, J. Revuz and J.C. Roujeau. 1995. Erythema multiforme with mucous membrane involvement and Stevens-Johnson syndrome are clinically different disorders with distinct causes. Arch. Dermatol. 131:539.
3. Roujeau J.C. 1997. Stevens-Johnson syndrome and toxic epidermal necrolysis are severity variants of the same disease which differs from erythema multiforme. J. Dermatol. 24:726.
4. Auquier-Dunant A., M. Mockenhaupt, L. Naldi, O. Correia, W. Schroder and J.C. Roujeau. 2002. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis. Arch. Dermatol. 138:1019.
5. Paul C., P. Wolkenstein, H. Adle, J. Wechsler, H.J. Garchon, J. Revuz and J.C. Roujeau. 1996. Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis. Br. J. Dermatol. 134:710.
6. Viard I., P. Wehrli, R. Bullani, P. Schneider, N. Holler, D. Salomon, T. Hunziker, J.H. Saurat, J. Tschopp and L.E. French. 1998. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 282:490.
7. Abe R., T. Shimizu, A. Shibaki, H. Nakamura, H. Watanabe and H. Shimizu. 2003. Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas Ligand. Am. J. Pathol. 162:1515.
8. Baetu T.M. and J. Hiscott. 2002. On the TRAIL to apoptosis. Cytokine Growth Factor Rev. 13:199.
9. Orrenius S. 2004. Mithochondrial regulation of apoptotic cell death. Toxicol. Lett. 149:19.
10. Nakagawa T., H. Zhu, N. Morishima, E. Li, J. Xu, B.A. Yankner and J. Yuan. 2000. Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-β. Nature 403:98.
11. Wehrli P., I. Viard, R. Bullani, J. Tschopp and L.E. French. 2000. Death receptors in cutaneous biology and disease. J. Invest. Dermatol. 115:141.
12. Baima B. and M. Sticherling. 2001. Apoptosis in different cutaneous manifestations of lupus erythematosus. Br. J. Dermatol. 144:958.
13. Moore N., M. Biour, G. Paux, E. Loupi, B. Beqaud, F. Boismare and R.J. Royer. 1985. Adverse drug reaction monitoring : doing it in the French way. Lancet 2:1056.
14. Lucotte G., C. Bathelier, V. Lespiaux, C. Bali and T. Champenois. 1995. Detection and genotyping of herpes simplex virus types 1 and 2 by polymerase chain reaction. Mol. Cell Probes 9:287.
15. Cordell J.L., B. Falini, W.N. Erber, A.K. Ghosh, Z. Abdulaziz, S. MacDonald, K.A. Pulford, H. Stein and D.Y. Mason. 1984. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J. Histochem. Cytochem. 32:219.
16. Roujeau J.C. 2000. Nécrolyse épidermique: les avancées physiopathogéniques. Ann. Dermatol. Venereol. 127:546.
17. Villada G., J.C. Roujeau, T. Clerici, I. Bourgault and J. Revuz. 1992. Immunopathology of toxic epidermal necrolysis. Arch. Dermatol. 128:50.
18. Miyauchi H., H. Hosokawa, T. Akaeda, H. Iba and Y. Asada. 1999. T-cell subsets in drug-induced toxic epidermal necrolysis. Arch. Dermatol. 1:851.
19. Le Cleach L., S. Delaire, L. Boumsell, M. Bagot, I. Bourgault-Villada, A. Bensussan and J.C Roujeau. 2000. Blister fluid T lymphocytes during toxic epidermal necrolysis are functional cytotoxic cells which express human natural killer (NK) inhibitory receptors. Clin. Exp. Immunol. 119:225.
20. Margolis R.J., M.G. Tonnesen, T.J. Harrist, A.K. Bhan, B.I.J. Wintroub, M.C. Mihm Jr and N.A. Soter. 1983. Lymphocyte subsets and Langerhans cell/indeterminate cells in erythema multiforme. J. Invest. Dermatol. 81(5):403.
21. Cohen J.J. and R.S. Duke. 1992. Apoptosis and programmed cell death in immunity. Annu. Rev. Immunol. 10:267.
22. Cohen J.J. 1993. Apoptosis. Immunol. Today 14:126.
23. Sayama K., S. Yonehara, Y. Watanabe and Y. Miki. 1994. Expression of Fas antigen on keratinocytes in vivo and induction of apoptosis in cultured keratinocytes. J. Invest. Dermatol. 103:330.
24. Iwai K., T. Miyawaki, T. Takizawa, A. Konno, K. Ohta, A. Yachie, H. Seki and N. Taniguchi. 1994. Differential expression of bcl-2 and susceptibility to anti-Fas-mediated cell death in peripheral blood lymphocytes, monocytes and neutrophils. Blood 84:1201.
25. Reed J.C. 1996. Mechanism of bcl-2 family protein function and dysfunction in health and disease. Behring Inst. Mitt. 97:72.
26. Liu H. and R.M. Pope. 2003. The role of apoptosis in rheumatoid arthritis. Curr. Opin. Pharmacol. 3:317.
27. Itoh N., Y. Tsujimoto and S. Nagata. 1993. Effect of bcl-2 on Fas antigen-mediated cell death. J. Immunol. 151:621.
28. Nakagawa K., K. Yamamura, S. Maeda and M. Ichihashi. 1994. Bcl-2 expression in epidermal keratinocytes disease. Cancer 74:1720.
29. Hockenbery D.M., M. Zutter, W. Hickey, M. Nahm and S.J. Korsmeyer. 1991. Bcl-2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc. Natl. Acad. Sci. USA 88:6961.
30. Oltvai Z.N., C.L. Miliman and S.J. Korsmeyer. 1993. Bcl-2 heterodimerizes in vivo with a conserved homolog Bax that accelerates programmed cell death. Cell 74:609.
31. Tomková H., W. Fujimoto and J. Arata. 1998. Expression of the Bcl-2 homologue Bax in normal human skin, psoriasis vulgaris and non-melanoma skin cancers. Eur. J. Dermatol. 8:256.